Scor­pi­on snags a Sanofi vet to lead the way to the clin­ic; All eyes on eli-cel as blue­bird seeks a fi­nance leader — again

Up­on tak­ing the helm at pre­ci­sion on­col­o­gy-fo­cused Scor­pi­on Ther­a­peu­tics last sum­mer, Ax­el Hoos told End­points News that he had a clear vi­sion of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.